Report #2897186

Received May 19, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: PA
Recovered: Unknown
Vaccinated: Apr 13, 2026
Onset: Apr 27, 2026
Days to onset: 14
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

The Second Dose of Heplisav-B Was Given Too Soon; Initial report received on 07-May-2026. A nurse reported that a male patient (race and ethnicity not reported) received the second dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization too soon. No medical history or concomitant medications were reported. On 13-Apr-2026, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number, expiration date, NDC #, route, and site not reported). On 27-Apr-2026, 15 days after receiving dose one of HEPLISAV-B, the patient received dose 2 of HEPLISAV-B (lot number, expiration date, NDC #, route, and site not reported). No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.

Medical history

Medical History/Concurrent Conditions: No adverse event